ENTITY
Sciclone Pharmaceuticals

Sciclone Pharmaceuticals (6600 HK)

103
Analysis
Health CareChina
SciClone Pharmaceuticals (Holdings) Limited operates as a biopharmaceutical company. The Company develops produces and sells oncology drug, infectious diseases drugs and other products. SciClone Pharmaceuticals (Holdings) markets its products throughout China.
more
bullishYidu Tech Inc
18 May 2021 10:26

HSCI Index Rebalance and Stock Connect: Potential Changes in June and September

A look at the potential changes to the HSCI at the June & September reviews and stocks that could be included in/excluded from Stock Connect. These...

Logo
514 Views
Share
bullishCoupang
14 Mar 2021 10:15

ECM Weekly (14th March 2021) - Coupang, Baidu, Shanghai Heartcare, Chaoju Eye Care, Linklogis, Tuya

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.

Share
02 Mar 2021 12:11

SciClone (赛生药业) IPO Trading: Bifurcation of Demand

We were bearish with the deal and with the recent correction in the market, we think there is a chance that the deal goes under water post listing.

Logo
299 Views
Share
bullishCheerwin
28 Feb 2021 11:23

ECM Weekly (28 February 2021) - Cheerwin, Coupang, DDMP REIT, Aztech, Autohome HK

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.

Share
22 Feb 2021 15:47

SciClone Pharmaceuticals IPO Valuation: Not Pleasing

SciClone has set the terms for its IPO, where it plans to issue approx. 116m shares at an indicative IPO price range of HK$17.2-18.8 per share to...

Share
x